Phio pharmaceuticals fintel

Author: gxlw

August undefined, 2024

Webb31 mars 2024 · Phio Pharmaceuticals to begin Phase 1b clinical trial with PH-762 for cSCC March 22, 2024TipRanks Phio Pharmaceuticals reports FY22 EPS ($10.10) vs. one estimate ($10.92) March 22,... Webb1 mars 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic...

PHIO Stock Financial Analysis - Phio Pharmaceuticals Corp

WebbPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update. Additional Formats PDF Version. February 22, 2024 Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer. Additional Formats PDF Version. February 13, 2024 ... WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in … porsche 997 4s mk2

PHIO - Phio Pharmaceuticals Corp. Stock Price and Quote

Webb6 apr. 2024 · Phio Pharmaceuticals (NASDAQ:PHIO) has a recorded net income of -$11.48 million. PHIO has generated -$10.68 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Call Transcripts … WebbPHIO - Phio Pharmaceuticals Corp. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save … WebbPhio Pharmaceuticals Our Science Our Science Overview Phio is addressing some of the biggest challenges in immuno-oncology (I/O) by developing therapeutics that leverage … sharps safety training video

PHIO / Phio Pharmaceuticals Corp - Institutional Ownership - fintel.io

PHIO Phio Pharmaceuticals Corp - Stocktwits

Webb10 apr. 2024 · Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. About the company Risk Analysis Earnings have declined by 8.5% per year over past 5 years Has less than 1 year of cash runway Makes less than USD$1m in revenue ($0) Does not have a meaningful market cap ($7M) + 2 more risks See All Risk Checks … WebbThe average one-year price target for Phio Pharmaceuticals is $73.44 The forecasts range from a low of $72.72 to a high of $75.60. Update Frequency: Monthly PHIO / Phio … porsche 997 alignment specsWebb359 rader · Phio Pharmaceuticals Corp insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is … sharps run shopping center

"WebbPHIO Stock Financial Analysis - Phio Pharmaceuticals Corp (NASDAQ) Stock. Fintel ... " - Phio pharmaceuticals fintel

Phio pharmaceuticals fintel

PHIO SEC Filings - Phio Pharmaceuticals Corp - Annual Report, …

WebbAt Phio Pharmaceuticals, our mission is to develop innovative cancer treatments that overcome tumor immunosuppression and weaponize the immune system against … WebbPhio Pharmaceuticals Corp (PHIO) Stock Price Today, News, Quotes, FAQs and Fundamentals 8.50% KRYS 4.70% INFY 0.46% FAST 0.66% UNL 3.55% More …

Did you know?

WebbPHIO / Phio Pharmaceuticals Corp Implied Volatility - Fintel Labs. Fintel ... WebbResumen PHIO Gráfico técnico Phio Pharmaceuticals Corp 5,527 + 0,259 ( + 4,92 %) S 1 semana 1 año Máx. Último cierre 5,268 Rango día 5,321 - 6 Ingresos - Apertura 5,321 52 semanas 3,9 - 29,04...

Webb30 mars 2024 · Phio Pharmaceuticals - PHIO News Today $5.99 +0.16 (+2.74%) (As of 03/30/2024 10:41 AM ET) Compare Today's Range $5.75 $5.99 50-Day Range $0.51 $6.85 52-Week Range $3.90 $29.04 Volume 1,039 shs Average Volume 36,447 shs Market Capitalization $6.89 million P/E Ratio N/A Dividend Yield N/A Price Target N/A Profile … WebbPHIO - Phio Pharmaceuticals Corp. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Intraday Daily Weekly Monthly Draw Fullscreen Settings PHIO - Stock Price Chart PHIO [NASD]

WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. WebbPhio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 (508) 767-3861 February 7, 2024 VIA EDGAR Securities and Exchange Commission Division of …

WebbPHIO / Phio Pharmaceuticals Corp - Net Long/Short Value This page provides the net long/short valuations for each institutional holding reported via 13F or NPORT filings. To …

Webb22 feb. 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. Corporate Presentation The following is an investor update, effective January 2024, presented by Robert Bitterman. Mr. porsche 997 a vendreWebbPhio Pharmaceuticals Corp (NASDAQ:PHIO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in … porsche 997.2 gts manual for sale ukWebbPhio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) … sharps service center watertown sdWebbDeutsche Bank Ag\ closes position in PHIO / Phio Pharmaceuticals Corp Institutional Ownership: 13F and NPORT Filings The Security and Class in the table below are shown … sharps school furnitureWebbPHIO Short Sale Transactions - Phio Pharmaceuticals Corp EXTENDED. Day's Range - 52 Week Range - sharps salvage woodstock sharps safety cdcWebb12 apr. 2024 · Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on … sharps sharpsinc.com